Zdrowie i gospodarka · 30/12/2013

FDA Reclassifies External Counter-Pulsating Devices for Chronic Stable Angina Treatment

The FDA is reclassifying external counter-pulsating devices for treating chronic stable angina that is resistant to standard medical treatment and lacks revascularization options, requiring manufacturers to submit premarket approval applications or product development protocols for other intended uses.